Skip to main content

Any Patient Treated With MB-105

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

March Biosciences
March BiosciencesTX - Houston
1 program
MB-105N/A1 trial
Active Trials
NCT07340814Not Yet Recruiting40Est. Oct 2040

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
2030
2031
March BiosciencesMB-105

Clinical Trials (1)

Total enrollment: 40 patients across 1 trials

A Long-term Follow-up Study of Patients Who Received MB-105

Start: Feb 2026Est. completion: Oct 204040 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.